The relationship between the control of pH and healing and symptom relief in gastro‐oesophageal reflux disease
- 1 April 1995
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 9 (s1) , 3-7
- https://doi.org/10.1111/j.1365-2036.1995.tb00777.x
Abstract
Gastro-oesophageal reflux disease (GERD) is generally considered to be the result of a motility disorder which permits the abnormal and prolonged exposure of the lumen of the oesophagus to the acidic gastric contents. This view is supported by experimental data, intra-oesophageal pH measurement, and the dramatic results of symptom relief and healing seen with effective antisecretory treatment. Oesophageal mucosal injury is determined by the pH of the refluxate and duration of acid exposure. Most patients experience meal-stimulated reflux during the day and the more severe cases experience 24-h acid exposure. In contrast to the H2-receptor antagonists (H2RAs), the proton pump inhibitors (PPIs) are more effective at controlling meal-stimulated acid secretion when each is given in standard doses. Therefore, the degree and duration of acid suppression throughout 24 h is greater. Treatments which maintain intra-oesophageal pH > 4 for 96% or more of the 24 h normalize acid exposure and are associated with the highest healing rates. Peptic activity is minimized at or above pH 4. The time above pH 4 is significantly longer with the PPIs than with the H2RAs. Thus, the healing-time curves for GERD (grades II-IV) are shifted to the left for the PPIs which heal a significantly greater proportion of patients earlier than the H2RAs or sucralfate. Symptoms in GERD are related to the degree and duration of oesophageal acid exposure. Symptom relief is more rapid and complete with the PPIs than with the H2RAs or other treatments in standard doses.Keywords
This publication has 25 references indexed in Scilit:
- Rolling review: gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1993
- Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaireAlimentary Pharmacology & Therapeutics, 1993
- Lansoprazole versus Omeprazole in Short-Term Treatment of Reflux Oesophagitis Results of a Scandinavian Multicentre TrialScandinavian Journal of Gastroenterology, 1993
- Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled studyAlimentary Pharmacology & Therapeutics, 1992
- Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagusDigestive Diseases and Sciences, 1992
- Appropriate Acid Suppression for the Management of Gastro-Oesophageal Reflux DiseaseDigestion, 1992
- Tolerance and rebound to H2-receptor antagonists: Intragastric acidity in patients with duodenal ulcerDigestive Diseases and Sciences, 1991
- Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist.Gut, 1988
- Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitisDigestive Diseases and Sciences, 1988
- Symptomatic gastroesophageal reflux: Incidence and precipitating factorsDigestive Diseases and Sciences, 1976